EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript Summary
EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript Summary
Net loss for the quarter was €6.4 million, or €0.17 per diluted share, compared to a net loss of €3.9 million, or €0.11 per diluted share, in the year-ago period.The following is a summary of the EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript:
以下是edap tms S.A.（edap）2024年第三季度業績會簡報：
Financial Performance:
財務業績：
EDAP TMS S.A. reported Q3 2024 total worldwide revenue of $14.4 million, achieving an 11.6% year-over-year growth in currency-adjusted terms.
Gross profit for Q3 was €5.2 million with a gross margin of 39.4%, showing an improvement from 35.5% in the previous year.
Net loss for the quarter was €6.4 million, or €0.17 per diluted share, compared to a net loss of €3.9 million, or €0.11 per diluted share, in the year-ago period.
edap tms S.A.報告了2024年第三季度全球總營業收入爲1440萬美元，在貨幣調整後的情況下實現了11.6%的年增長。
第三季度毛利潤爲520萬歐元，毛利率爲39.4%，與上一年的35.5%相比有所改善。
本季度淨虧損爲640萬歐元，每股稀釋收益爲0.17歐元，相比之下，去年同期的淨虧損爲390萬歐元，每股稀釋收益爲0.11歐元。
Business Progress:
業務進展:
EDAP placed three new Focal One systems during Q3, including their first at Virginia Commonwealth University.
Announced a strategic collaboration with Avenda Health, incorporating AI into the Focal One platform for prostate cancer treatment.
Initiated a combined Phase I/II study evaluating Focal One for treating benign prostatic hyperplasia (BPH).
Reported positive interim results in a Phase III study for treating deep infiltrating endometriosis with their robotic HIFU technology.
edap在第三季度安裝了三臺新的Focal One系統，其中包括他們在弗吉尼亞聯邦大學的第一臺。
宣佈與Avenda Health達成戰略合作，將人工智能應用於Focal One平台，用於前列腺癌治療。
啓動了一項綜合的I/II期研究，評估Focal One用於治療良性前列腺增生（BPH）。
報告了一項針對深部浸潤性子宮內膜異位症的III期研究中的積極中期結果，使用他們的機器人HIFU技術。
Opportunities:
機會：
The continued adoption of Focal One by leading U.S. cancer treatment centers represents a significant growth opportunity.
The favorable reimbursement rates set for 2025 by CMS for HIFU procedures bolster the financial case for greater adoption in hospitals.
Focal One在美國主要癌症治療中心持續被採用，代表着顯著的增長機會。
CMS爲2025年設定的HIFU程序有利的報銷率，增強了醫院更多采用的財務案例。
Risks:
風險：
The gradual growth in the adoption of the AI-assisted Focal One procedures and the new clinical programs can present challenges, with outcomes influencing future adoption rates.
人工智能輔助的Focal One程序和新的臨床項目逐漸增長的採用量可能會帶來挑戰，其結果會影響未來的採用率。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
